Department of Epidemiology, Erasmus Medical Center, Rotterdam. The Netherlands.
Br J Clin Pharmacol. 2012 Dec;74(6):1045-52. doi: 10.1111/j.1365-2125.2012.04310.x.
Cardiovascular disease in women is often underestimated. The effects of cardiovascular drugs differ between the sexes because of pharmacokinetic and pharmacodynamic differences. Adverse drug reactions (ADRs) within these drug classes may have serious consequences, leading to hospital admission. We aimed to study differences between men and women in hospital admissions for ADRs due to cardiovascular drugs.
We conducted a nationwide study of all hospital admissions between 2000 and 2005 with data from the Dutch National Medical Register. Relative risks were calculated of hospital admissions due to ADRs to the different cardiovascular drug groups for women compared with men. By an ecological design, risks were adjusted for the total number of Dutch inhabitants and the total number of prescriptions.
In total, 14 207 of the hospital admissions (34% of all ADR-related admissions) were attributed to cardiovascular drugs [7690 in women (54%; 95% confidence interval 53-55%)]. 'Anticoagulants and salicylates' (n= 8988), 'high- and low-ceiling diuretics' (n= 2242) and 'cardiotonic glycosides' (n= 932) were responsible for the majority of the ADR-related hospital admissions. The most pronounced sex differences were seen in users of low-ceiling diuretics (relative risk 4.02; 95% confidence interval 3.12-5.19), cardiotonic glycosides (relative risk 2.38; 95% confidence interval 2.06-2.74), high-ceiling diuretics (relative risk 2.10; 95% confidence interval 1.91-2.32) and coronary vasodilators (relative risk 0.77; 95% confidence interval 0.65-0.91).
Clear sex differences exist in ADRs requiring hospital admission for different cardiovascular drug groups. Sex differences should be taken into account in the prescription and evaluation of drugs.
女性的心血管疾病常常被低估。由于药代动力学和药效动力学的差异,心血管药物对男女的影响也不同。这些药物类别中的药物不良反应(ADR)可能会产生严重后果,导致住院。我们旨在研究因心血管药物导致的 ADR 住院治疗中男女之间的差异。
我们对 2000 年至 2005 年间所有来自荷兰国家医疗登记处的数据进行了全国性研究。我们计算了女性与男性相比,因不同心血管药物组的 ADR 而住院的相对风险。通过生态设计,根据荷兰居民总数和总处方数对风险进行了调整。
共有 14 207 例(所有 ADR 相关住院的 34%)归因于心血管药物[女性 7690 例(54%;95%置信区间 53-55%)]。“抗凝剂和水杨酸盐”(n=8988)、“高低限利尿剂”(n=2242)和“强心苷”(n=932)是导致 ADR 相关住院的主要原因。在使用低限利尿剂(相对风险 4.02;95%置信区间 3.12-5.19)、强心苷(相对风险 2.38;95%置信区间 2.06-2.74)、高限利尿剂(相对风险 2.10;95%置信区间 1.91-2.32)和冠状血管扩张剂(相对风险 0.77;95%置信区间 0.65-0.91)的患者中,性别差异最为显著。
不同心血管药物组因 ADR 而需要住院治疗的患者存在明显的性别差异。在药物的处方和评估中应考虑到性别差异。